Harrow, Inc.
HROWHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHarrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. At a $1.44B market cap, Harrow, Inc. ranks as a small-cap company within healthcare. It operates through Branded and ImprimisRx segments.
Market Cap
$1.44B
Beta
0.24
P/E (TTM)
—
P/E (Fwd)
14.08
EPS (TTM)
$-0.99
EPS (Fwd)
$2.74
ROE
-116.1%
ROA
-0.4%
Cash
$85.3M
Total Debt
$300.7M
Free CF
-$5.5M
52W Change
-1.9%
Annual Financials
Cash vs Debt
Where HROW stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, HROW finished 7.35% below its 150-day moving average ($39.84) and 10.65% below its 200-day moving average ($41.31). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HROW overbought or oversold?
At the September 1, 2026 close, HROW's RSI(14) was 40.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, HROW has $85.3M in cash with $300.7M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$5.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -116.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $88.6M (2022) to $272.3M (2025), reflecting a 207% increase over the period.
The relatively low beta of 0.24 suggests HROW is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Harrow, Inc.'s trajectory.